Dr. Jolene Faye Meis, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 194 6th Ave Ne, Le Mars, IA 51031 Phone: 712-546-3645 Fax: 712-546-3644 |
News Archive
INSYS Therapeutics, Inc. announces positive results from the pivotal phase III efficacy trial for patients utilizing the Fentanyl Sublingual Spray technology to treat breakthrough cancer pain. All primary and secondary endpoints were achieved in the study, and the drug is the first product to ever show statistically significant pain relief when measuring the summary of pain intensity difference at five minutes in a phase III breakthrough cancer pain trial using Fentanyl.
A new study has found that patients with chronic myeloid leukemia (CML) who have not responded to interferon treatments experience long-term benefits when they switch to the targeted drug imatinib.
The rate of teenage and younger girls giving birth in U.S. hospitals dropped by a quarter between 1997 and 2004 - from 55 to 41 admissions per 100,000 girls under age 18 - according to the latest News and Numbers from the Agency for Healthcare Research and Quality.
Treating pregnant women with selective serotonin reuptake inhibitors (SSRIs) appears to be associated with fewer depressive symptoms, reduced fetal head growth and a higher risk for preterm birth, but not with a delay in fetal body growth, according to a report published Online First by Archives of General Psychiatry, one of the JAMA/Archives journals.
Mitochondria are restless, continually merging and splitting. But contrary to conventional wisdom, the size of these organelles depends on more than fusion and fission, as Berman et al. show. Mitochondrial growth and degradation are also part of the equation.
› Verified 2 days ago